ClinicalTrials.gg

Glaucoma, Open-Angle clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 924 studies for Glaucoma, Open-Angle across more than 10 countries. 115 are recruiting or about to start. 865 of them are mainly about Glaucoma, Open-Angle (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-16. Counting its narrower condition Hydrophthalmos too: 960 studies, 117 open.

ClinicalTrials.gov finds 1,086 studies for Glaucoma, Open-Angle. How that becomes 922 here

This page counts the studies the registry files under Glaucoma, Open-Angle, and those it files under no condition that list Glaucoma, Open-Anglethemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 8, 2026. How condition pages count

  1. 1,086Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
  2. −36Filed under a narrower condition, counted on its own pageHydrophthalmos 36
  3. −11List Glaucoma, Open-Angle as a condition, but the registry did not file them under itMost often written as “Primary Open Angle Glaucoma of Both Eyes” (3), “Subjects With Primary Open-angle Glaucoma (POAG)” (1), and “Subject With Primary Open-angle Glaucoma (POAG)” (1). The registry filed them under other conditions only, most often Glaucoma (9) and Ocular Hypertension (3).
  4. −117Match it another way103 name it in the title, 3 in a keyword, and 11 by a synonym or other text the search reads.
  5. 922The count on this page4 of them list Glaucoma, Open-Angle in their own words; the registry filed them under no condition.

Status

Completed
577
Status unknown
91
Recruiting
82
Terminated
66
Active, not recruiting
42
Withdrawn
28

Phase

Phase 3
146
Phase 2
143
Phase 4
135
Phase 1
58
Early Phase 1
3

Where

United States
348
Germany
64
Spain
47
Canada
41
China
38
Italy
35

Who develops what

Add Glaucoma, Open-Angle to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 17 programs from 13 companies, 16 with this as their studies’ main aim; 6 with a live phase 3 study; 5 primary completions in the next 12 months. Compare Glaukos, Huons Global and Ache Laboratorios Farmaceuticos here →

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
LatanoprostRecent, repeated
Evidence
  • NCT07354516 · Qlaris Bio, Inc. · Phase 3 · comparator · “Latanoprost (0.005%)” · registered Jan 2026
  • NCT06964191 · PolyActiva Pty Ltd · Phase 2 · live · background · “Latanoprost 0.005% Ophthalmic Solution” · registered Mar 2025
  • NCT06666855 · Santen Pharmaceutical Co., Ltd. · Phase 3 · live · comparator · “Latanoprost” · registered Oct 2024
  • NCT06441643 · Alcon · Phase 2 · comparator · “Latanoprost 0.005% Ophthalmic Solution” · registered May 2024
  • NCT05583474 · Otsuka Holdings Co., Ltd. · Phase 3 · comparator · “0.005% Latanoprost” · registered Oct 2022
Viatris Inc.25% of its industry studiesUS: off-patent, 6 generics marketedEU: Santen Pharmaceutical Co., Ltd. (EMA 2023)56 studies
TimololRecent, repeated
Evidence
  • NCT07913074 · Tavo Biotherapeutics · Phase 2 · live · comparator · “Timolol 0.05% eye drops” · registered Oct 2026
  • NCT07495852 · Glaukos Corporation · Phase 3 · live · comparator · “Timolol eye drops 0.5%” · registered Mar 2026
  • NCT07075718 · Glaukos Corporation · Phase 2 · live · comparator · “Timolol eye drops 0.5%” · registered Jul 2025
  • NCT06152861 · Glaukos Corporation · Phase 2 · live · comparator · “Timolol maleate ophthalmic solution, 0.5%” · registered Nov 2023
  • NCT05913232 · D. Western Therapeutics Institute, Inc. · Phase 2 · comparator · “Timolol 0.5%” · registered Jun 2023
AbbVie30% of its industry studiesUS: off-patent, 43 generics marketed35 studies

7 more in limited or earlier use — sign in to see them, free.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

In phase 3Company
HUC3-637☆ Track1 live phase-3 study: NCT07335211Huons Global
HUC3-637-R☆ Track1 live phase-3 study: NCT07335211Huons Global
Bimatoprost Ophthalmic SolutionPhase 4 trial recorded☆ Track1 live phase-3 study: NCT07661329YS Life Science Co., Ltd.
Product DNN.31.19.026☆ Track1 live phase-3 study: NCT07617532Ache Laboratorios Farmaceuticos S.A.
TravoprostApproved: US · EU 2001☆ Track1 live phase-3 study: NCT06061718Glaukos Corporation

The 5 in phase 3 with the nearest primary completion, of 17 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (5)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • 30 Jun 2027 est.Arm 1: TB0001 ophthalmic solution 0.9% · Tavo Biotherapeutics · Phase 2 main aimvs TimololNCT07913074 A Phase 2a Study Comparing the Efficacy, Safety and Tolerability of Pregabalin Eye Drops Comparing With Timolol Eye Drops in Adults With Glaucoma or High Eye Pressure. — primary endpoint: Change from mean diurnal baseline IOP to mean diurnal IOP at Day 28 · 96 enrolled
  • 10 Jul 2027 est.Biomarkers · Tecnoquimicas · Phase 4 main aimNCT07690397 Dorzolamide/Brimonidine/Timolol Impact on Ocular Surface, Glaucoma Progression & Chatbot Follow-up: GLAUCO-TECH — primary endpoint: Changes in efficacy and quality of life and adherence questionnaires between two different formulations · 140 enrolled
  • 1 Oct 2027 est.G01 Eye Drops 100μg/ml, G01 Eye Drops 200μg/ml · Qingdao WanMing BioCell Pharmaceutics Co.,Ltd. · Phase 2 main aimNCT07777861 A Phase II Trial of G01 Eye Drops for Glaucomatous Optic Neuropathy — primary endpoint: Change from Baseline in Mean Deviation (MD) of Visual Field · 90 enrolled

2 more — sign in to see them all, free.

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Glaucoma, Open-Angle studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Beta blockers 33 · Corticosteroids 4

Coming up

52studies finish main data collection within a year5 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 82 Glaucoma, Open-Angle studies recruiting now, 63 (77%) set no upper age limit and 5 (6%) stop at 75 or younger. 5 (6%) take children under 18. 1 (1%) are for women only and 0 (0%) for men only; 11 (13%) take healthy volunteers.

Recruiting studies that take each age, of 82
AgeWomenMen
104 (5%)4 (5%)
1850 (61%)50 (61%)
3061 (74%)61 (74%)
4073 (89%)73 (89%)
5080 (98%)80 (98%)
6581 (99%)80 (98%)
7581 (99%)80 (98%)
8574 (90%)74 (90%)

Across all 924 studies, recruiting or not: 6% stop at 75 or younger and 2% at 65; 6% take children; <1% are for women only and <1% for men only; 14% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Glaucoma, Open-Angle studies take

Of 49 phase 3 interventional studies under Glaucoma, Open-Angle, half reached primary completion within 26 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 115 mo7–23 · 17 studies——
Phase 211 mo7–18 · 41 studies11 mo6–16 · 38 studies—
Phase 326 mo12–39 · 49 studies26 mo12–39 · 47 studies—
Phase 420 mo14–37 · 45 studies——
Interventional, no phase35 mo19–61 · 171 studies33 mo19–64 · 70 studies35 mo18–57 · 101 studies
Observational25 mo12–… · 53 studies——

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 18, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 924. Browse all 924 → or search them.